相关实验视频

Updated: Jul 24, 2025

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

通过蛋白质工程来准Ras

Atilio Tomazini¹, Julia M Shifman¹

¹Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 9190401, Israel.

|July 3, 2023

概括

在癌症中准Ras蛋白是具有挑战性的. 蛋白质工程提供了一种抑制各种Ras突变的新策略,克服了小分子药物的局限性,并推进了癌症治疗.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

拉斯蛋白是细胞生长的关键调节者,它们的突变驱动癌症的发展.
由于它们的结构,以小分子准Ras蛋白很困难,尽管在特定的突变中取得了一些成功.
现有的疗法通常只针对Ras G12C突变,使其他致癌Ras变体无法用类似的方法治疗.

研究的目的:

探索蛋白质工程作为针对各种Ras瘤基因突变的新策略.
审查工程抗Ras剂及其治疗机制的最新进展.
突出蛋白质工程在克服Ras向癌症治疗中的挑战方面的潜力.

主要方法:

关于Ras蛋白功能,突变和向治疗的科学文献的综述.
分析蛋白质工程方法,包括工程抗体,效应器和结合域.
检查工程蛋白质用来抑制Ras活动的策略.
评估细胞内蛋白质输送系统的进展.

主要成果:

蛋白质工程使得能够开发出对各种Ras表面具有高亲和度和特异性的剂.
工程蛋白质可以通过破坏效应因子相互作用,二元化或核酸交换来抑制Ras.
其他策略包括促进瘤抑制剂相互作用或Ras降解.
细胞内传递的进步促进了这些工程制剂的细胞质传递.

结论:

蛋白质工程提供了一种多功能和有前途的方法来准癌症中更广泛的Ras突变谱.
这一策略克服了当前小分子抑制剂的局限性,特别是对于非G12C突变物.
工程蛋白质的成功细胞内输送为开发有效的抗癌疗法,以对抗像Ras.

关键词:

在 Ras 瘤基因基因上.拉斯的目标定位是针对目标的.反拉斯治疗药物治疗.蛋白质设计蛋白质设计蛋白质工程工程蛋白质工程

更多相关视频

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Inducible and Reversible Dominant-negative DN Protein Inhibition

Inducible and Reversible Dominant-negative DN Protein Inhibition

Published on: January 7, 2019

相关概念视频

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...

Small GTPases - Ras and Rho

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Conservative Site-specific Recombination and Phase Variation

Conservative Site-specific Recombination and Phase Variation

Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...